Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Dividend Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023

Icosavax Inc Dividend Coverage Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The dividend coverage ratio measures a company's ability to cover its dividend payments with its net income. It is calculated by dividing net income by dividends paid. This ratio indicates the proportion of net income that is allocated to paying dividends. A ratio greater than 1 suggests sufficient income to cover dividend payments, while a ratio less than 1 indicates a potential shortfall.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends